Compare GVH & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GVH | APRE |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 10.6M |
| IPO Year | 2023 | 2019 |
| Metric | GVH | APRE |
|---|---|---|
| Price | $6.00 | $0.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $80.00 | $4.10 |
| AVG Volume (30 Days) | 150.7K | ★ 291.1K |
| Earning Date | 02-17-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $102,768.97 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $0.55 |
| 52 Week High | $10.74 | $2.22 |
| Indicator | GVH | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 85.92 | 49.89 |
| Support Level | $4.02 | $0.57 |
| Resistance Level | N/A | $0.98 |
| Average True Range (ATR) | 0.65 | 0.08 |
| MACD | 0.23 | -0.01 |
| Stochastic Oscillator | 89.05 | 19.60 |
Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.